Doctor of Science

Brain & Behavior Research Foundation Awards Distinguished Investigator Grants Valued at $1 Million to 10 Scientists Pursuing Innovative Mental Health Research

Retrieved on: 
Thursday, April 4, 2024
Depression, Patient, Mitochondrion, Doctor of Science, Harvard University, Therapy, Research, Risk, Mental health, University of Pittsburgh, Brain, DSM-IV codes, Brown University, Cannabis, Memory, Safety, Spectrum, Mitophagy, Schizophrenia, Hippocampus, Bipolar disorder, Anxiety, Learning, University, Psychopathology, Cerebrospinal fluid, University of California, Distinguishing, PET, Biomarker, Hope, Baylor College of Medicine, Behavior, AMPA, Fragile X syndrome, PTSD, Pharmaceutical industry

New York, April 04, 2024 (GLOBE NEWSWIRE) -- The Brain & Behavior Research Foundation (BBRF) today announced it is awarding Distinguished Investigator Grants valued at $1 million to 10 senior-level scientists who are conducting innovative projects in neurobiological and behavioral research.

Key Points: 
  • New York, April 04, 2024 (GLOBE NEWSWIRE) -- The Brain & Behavior Research Foundation (BBRF) today announced it is awarding Distinguished Investigator Grants valued at $1 million to 10 senior-level scientists who are conducting innovative projects in neurobiological and behavioral research.
  • By funding transformative research focused on new ways to prevent, diagnose, and treat psychiatric disorders, our Distinguished Investigator Grants are encouraging established scientists to continue advancing our understanding of mental illness and disorders of brain and behavior,” says Jeffrey Borenstein, M.D., President and CEO of the Brain & Behavior Research Foundation.
  • The ground-breaking work of the Distinguished Investigator Grant recipients will bring hope and healing to people and families impacted by mental illness.
  • We applaud these scientists for their extraordinary dedication, innovation, and leadership.”
    Recipients of the Distinguished Investigator Grants are full professors at research institutions in the United States and abroad.

SELLAS Life Sciences Reports Full Year 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, March 28, 2024
Ovarian cancer, SLS, Survival, Lymphoma, Fast track (FDA), PTCL, National Cancer Institute, CMC, Clinical trial, Committee, Research, NCI, European School, Bone marrow, AML, GPS, Pembrolizumab, Doctor of Science, Nivolumab, Safety, MRD, CDK9, BLA, Food, CR2, Zanubrutinib, Mesothelioma, BIW, MD, Completeness, WT1, FDA, DLBCL, IDMC, Therapeutic index, Type, Fast Track, Biomarker, BTK, Pharmaceutical industry

The SLS009 aza-ven treatment was well-tolerated and evoked anti-leukemic effects in 67% of patients across all levels dosed.

Key Points: 
  • The SLS009 aza-ven treatment was well-tolerated and evoked anti-leukemic effects in 67% of patients across all levels dosed.
  • The first patient who achieved a complete response continues on the study and remains leukemia-free 9 months post-enrollment.
  • The net proceeds from the offering strengthen the Company’s financial position and will be used for research and development activities, working capital, and general corporate purposes.
  • Cash Position: As of December 31, 2023, cash and cash equivalents totaled approximately $2.5 million.

Aligos Therapeutics Presents Positive Clinical Data at APASL 2024 from ALG-055009 and ALG-000184 Phase 1 Studies

Retrieved on: 
Wednesday, March 27, 2024
Multiple, Professor, ETV, SAN, Patient, Hepatology, Southern Medical University, SHBG, Doctor of Science, University, Doctor of Philosophy, MBBS, MASH, MBA, Science, Therapy, Hepatitis, Part, Division, University of Hong Kong, Infection, CHB, Pharmaceutical industry

The poster presentation highlights ALG-055009 Phase 1 data that showed multiple-ascending doses (MAD) over 14 days in hyperlipidemic subjects produced favorable, dose-dependent pharmacodynamic effects on atherogenic lipids and sex hormone binding globulin (SHBG), an indicator of target engagement in the liver.

Key Points: 
  • The poster presentation highlights ALG-055009 Phase 1 data that showed multiple-ascending doses (MAD) over 14 days in hyperlipidemic subjects produced favorable, dose-dependent pharmacodynamic effects on atherogenic lipids and sex hormone binding globulin (SHBG), an indicator of target engagement in the liver.
  • “We are pleased to present these additional Phase 1 data for ALG-055009 and ALG-000184 at APASL 2024.
  • We continue to believe our molecule has the potential to be best-in-class,” said Lawrence Blatt, Ph.D., MBA, Chairman, President, and Chief Executive Officer at Aligos Therapeutics.
  • “In addition, the three ALG-000184 oral presentations demonstrate a consistent effect in the reduction of key viral markers.

SELLAS Announces Positive Topline Data from the Phase 2a Study of SLS009 in r/r AML and Provides Steering Committee Update on Phase 3 REGAL Study

Retrieved on: 
Tuesday, March 26, 2024
Corporation, Toxicity, SLS, Survival, AML, Committee, Biomarker, GPS, Death, BIW, Enrollment, MD, Date, Trial of the century, Doctor of Science, Safety, IDMC, Pharmaceutical industry

The Company will host a webinar to discuss the data and the REGAL update today at 8:15 am ET.

Key Points: 
  • The Company will host a webinar to discuss the data and the REGAL update today at 8:15 am ET.
  • “We are extremely grateful to the patients, their families, and investigators who have helped us achieve this significant milestone.
  • Additionally, we are pleased to share that the Steering Committee has reviewed the study as of the March 1, 2024, cutoff date.
  • Dr. Stergiou continued: “We are extremely excited to share positive topline data from the Phase 2a trial of SLS009 in AML patients resistant to venetoclax combination therapies.

SELLAS Life Sciences to Host Corporate Update Call on March 26, 2024, at 8:15 am ET

Retrieved on: 
Tuesday, March 19, 2024
MD, GPS, SLS, Doctor of Science, Corporation, AML

NEW YORK, March 19, 2024 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced that it will host a corporate update call on March 26, 2024, at 8:15 am ET.

Key Points: 
  • -  Update on the Phase 2a Clinical Trial of SLS009 in relapsed/refractory AML, including topline data -
    NEW YORK, March 19, 2024 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced that it will host a corporate update call on March 26, 2024, at 8:15 am ET.
  • Angelos Stergiou, MD, ScD h.c., President and CEO of SELLAS will provide an update on the Phase 3 REGAL study of galinpepimut-S (GPS) in AML, as well as the topline data for the 45mg cohort and preliminary data for the 60mg cohort from the Phase 2a study of SLS009 in relapsed/refractory AML.
  • Corporate update call details are as follows:

SELLAS Announces Executive Leadership Reorganization and Prioritization of Commercialization Partnerships

Retrieved on: 
Friday, March 8, 2024
Senior, AML, MD, Stifel, PTCL, General counsel, GPS, Associate, Doctor of Science, SLS, Corporation

As part of this effort, Senior Vice President, Chief Commercial Officer, Robert Francomano and Executive Vice President, General Counsel and Corporate Secretary, Barbara Wood, will be departing the Company.

Key Points: 
  • As part of this effort, Senior Vice President, Chief Commercial Officer, Robert Francomano and Executive Vice President, General Counsel and Corporate Secretary, Barbara Wood, will be departing the Company.
  • “As part of our efforts to rapidly advance our clinical pipeline, we continue to streamline our operations to effectively and efficiently deliver on our key business objectives,” said Angelos Stergiou, MD, ScD h.c., President and Chief Executive Officer of SELLAS.
  • “As I mentioned on the January shareholder call, our focus remains on shareholder value through the development of our assets and tight financial stewardship and exploration of commercial partnerships with the assistance of Stifel Financial Corp.
  • Stacy Yeung, recently promoted to Vice President, Associate General Counsel, and Head of Compliance, with 20 years of relevant experience will lead the Company’s legal and compliance functions.

Lifezone Metals Announces Two-Phased Development Plan for the Kabanga Nickel Project in Tanzania

Retrieved on: 
Monday, February 26, 2024
Environment, Other Energy, Engineering, Alternative Energy, Manufacturing, Energy, Mining, Minerals, Natural Resources, Science, Other Science, Nickel, Doctor of Science, Copper, Royal Society of Chemistry, Doctor of Philosophy, Multimedia, News, Metallurgy, Safety, LZM, Kabanga Nickel Project, Cobalt, Institute for Colored Youth, Environmental impact assessment, Composite, Metal, Rare-earth element

Lifezone Metals has determined that a two-phase development plan for its Kabanga Nickel Project will form the base case of the Definitive Feasibility Study.

Key Points: 
  • Lifezone Metals has determined that a two-phase development plan for its Kabanga Nickel Project will form the base case of the Definitive Feasibility Study.
  • The Company continues to collaborate closely with its project partner on this two-phased development plan, as well as numerous other Definitive Feasibility Study work streams.
  • Lifezone Metals is working to evolve and integrate sustainability across Project planning, implementation and in-country operational readiness.
  • Ongoing refinement of the development plan and metallurgical testing is aimed at maximizing the net present value of the Project while optimizing capital outlays.

The American Diabetes Association Announces the 2024 National Scientific and Health Care Achievement Award Winners

Retrieved on: 
Wednesday, March 6, 2024
Reward, Bachelor of Science, Nursing, Royal College of Pathologists, Doctor of Philosophy, Pregnancy, University, FRCP, CUPS, Social media, American Diabetes Association, Doctor of Science, MB, FESC, Lois Jovanovic, FACP, FACE, FACC, MRCP, Book, Physician, Female, Doctor of Pharmacy, Life, Learning, Prognosis, Prediabetes, Insulin resistance, Lond, Research, FAHA, Interest, Patient, Causality, Public

ARLINGTON, Va., March 6, 2024 /PRNewswire/ -- The American Diabetes Association® is pleased to announce this year's National Scientific and Health Care Achievement Award recipients.

Key Points: 
  • ARLINGTON, Va., March 6, 2024 /PRNewswire/ -- The American Diabetes Association® is pleased to announce this year's National Scientific and Health Care Achievement Award recipients.
  • The awards honor academics, health care providers, and educators who have contributed to substantial advances in diabetes care and research.
  • ), FMedSci is the recipient of the 2024 Banting Medal for Scientific Achievement, which recognizes significant long-term contributions to the understanding, treatment, or prevention of diabetes.
  • Parker, PhD is the recipient of the 2024 Outstanding Scientific Achievement Award, which recognizes research in diabetes that demonstrates particular independence of thought and originality.

Calling on the Medical Establishment to Teach Leadership As a Core Competency

Retrieved on: 
Tuesday, February 20, 2024
FACS, Doctor of Science, Education, Physician, Behavior, Lead, Patient, Nursing

NEW YORK, Feb. 20, 2024 /PRNewswire/ -- All Physicians Lead: Redefining Physician Leadership for Better Patient Outcomes, by Leon E. Moores, MD, DSc, FACS, is now available. The book is published with Forbes Books, the exclusive business book publishing imprint of Forbes, and is available on Amazon today.

Key Points: 
  • The book is published with Forbes Books, the exclusive business book publishing imprint of Forbes, and is available on Amazon today.
  • With his new book, Leon Moores delivers a clear message to physicians at every career stage: you're a leader.
  • Yet, few physicians ever receive any focused leadership training as they matriculate through medical school, internships, residency programs, and late career stages.
  • "Physicians should be trained in leadership as a core competency from the start of medical school, throughout their residencies, and throughout their entire careers," Moores said.

Plant-Based Diet Tied to Improved Sexual Health in Men Treated for Prostate Cancer

Retrieved on: 
Tuesday, February 13, 2024
Master of Science, Bangladesh Technical Education Board, Nut, Prostate Cancer Foundation, Obstruction, Diabetes, Population health, Diet, National Institutes of Health, Prostate cancer, Dentist, Quality of life, Public health, Plant, Urinary incontinence, Harvard University, Hope, Veterinarian, Dietary fiber, SCM, Hot, Erectile dysfunction, Radiation, Meat, Risk, Pharmacist, University, NYU, Vegetable, History, Incontinence, Doctor of Science, White, Patient, MPH, Eating, Depression, Disease, NYU Langone Health, Male, Optometry, Research, Irritation, Dietary supplement

Chan School of Public Health, the analysis of more than 3,500 men with prostate cancer explored whether eating a more plant-based diet was associated with quality-of-life issues that often arise after treatment.

Key Points: 
  • Chan School of Public Health, the analysis of more than 3,500 men with prostate cancer explored whether eating a more plant-based diet was associated with quality-of-life issues that often arise after treatment.
  • Similarly, the results revealed up to 14% better scores for urinary health, with fewer instances of incontinence, obstruction, and irritation.
  • Prostate cancer is among the most common and deadliest forms of cancer among American men, according to the U.S. Centers for Disease Control and Prevention.
  • Funding for the study was provided by National Institutes of Health grant U01CA167552, New York State Department of Health, Tricia and Michael Berns, and the Prostate Cancer Foundation.